https://endeavorbiomedicines.com/wp-content/uploads/precision-oncology-logo-1.svg
52
273
Emily Hennes
/wp-content/uploads/logo.png
Emily Hennes2022-01-19 15:48:062022-01-31 17:59:11Endeavor BioMedicines Licenses ULK1/2 Inhibitor Program From Salk Institute, Sanford Burnham Prebys
https://endeavorbiomedicines.com/wp-content/uploads/techcrunch-logo-1.svg
52
364
Emily Hennes
/wp-content/uploads/logo.png
Emily Hennes2022-01-19 15:49:162022-01-19 15:49:16Endeavor BioMedicines raises $62 million to combat pulmonary disease
https://endeavorbiomedicines.com/wp-content/uploads/PF_News_logo-gray-01.svg
100
100
Emily Hennes
/wp-content/uploads/logo.png
Emily Hennes2022-01-19 15:47:182022-02-01 18:52:241st Patient Dosed in Trial of IPF Therapy Candidate Taladegib
https://endeavorbiomedicines.com/wp-content/uploads/scrip-logo-1.svg
52
169
Emily Hennes
/wp-content/uploads/logo.png
Emily Hennes2022-01-19 15:50:002022-01-19 15:50:00Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly
https://endeavorbiomedicines.com/wp-content/uploads/Stat_News_logo-gray.svg
100
100
Emily Hennes
/wp-content/uploads/logo.png
Emily Hennes2022-01-21 17:34:072022-01-21 17:47:16Serial biotech entrepreneur John Hood raises $62 million for company aimed at deadly lung disease
https://endeavorbiomedicines.com/wp-content/uploads/linkedin-gray.svg
100
100
Emily Hennes
/wp-content/uploads/logo.png
Emily Hennes2022-01-31 18:09:392022-02-01 18:52:55My newest puzzle, Endeavor BioMedicines, and the chance to reverse a devastating pulmonary disease
Scroll to top
